Differential expression and function of CYP2C isoforms in human intestine and liver

Pharmacogenetics

Volumn 13, Issue 9, 2003, Pages 565-575

  Läpple, Florian ^a   Von Richter, Oliver ^a   Fromm, Martin F ^a   Richter, Tanja ^a   Thon, Klaus P ^b   Wisser, Hermann ^c   Griese, Ernst Ulrich ^a   Eichelbaum, Michel ^a   Kivistö, Kari T ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CYP2C18; CYP2C19; CYP2C8; CYP2C9; Expression; Function; Genotype; Intestine; Liver

Indexed keywords

CYTOCHROME P450 2C; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; DICLOFENAC; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE CONTROL; GENE EXPRESSION; GENETIC IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROXYLATION; IMMUNOBLOTTING; INTESTINE; LIVER; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC MARKERS; HUMANS; INTESTINE, SMALL; INTESTINES; ISOENZYMES; LIVER; MALE; MIDDLE AGED; RNA, MESSENGER;

EID: 0141831861     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200309000-00005     Document Type: Article

References (34)

1. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270:414-423.
2. Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4:285-299.
3. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52:349-355.
4. Klose TS, Blaisdell JA, Goldstein JA. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol 1999; 13:289-295.
5. Richardson TH, Griffin KJ, Jung F, Raucy JL, Johnson EF. Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys 1997; 338:157-164.
6. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 2001; 29:242-251.
7. Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol 2003; 17:27-41.
8. de Waziers I, Cugnenc PH, Yang CS, Leroux JR, Beaune PH. Cytochrome P-450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990; 253:387-394.
9. Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS. Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 1999; 27:804-809.
10. Obach RS, Zhang QY, Dunbar D, Kaminsky LS. Metabolic characterization of the major human small intestinal cytochrome P450s. Drug Metab Dispos 2001; 29:347-352.
11. Glaeser H, Drescher S, van der Kuip H, Behrens C, Geick A, Burk O, et al. Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters. Clin Pharmacol Ther 2002; 71:131-140.
12. Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, et al. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 1999; 27:161-166.
13. Doherty MM, Charman WN. The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin Pharmacokinet 2002; 41:235-253.
14. Hülsmann WC, van den Berg JW, de Jonge HR. Isolation of intestinal mucosa cells. Methods Enzymol 1974; 32:665-673.
15. Futscher BW, Blake LL, Gerlach JH, Grogan TM, Dalton WS. Quantitative polymerase chain reaction analysis of mdr1 mRNA in multiple myetoma cell lines and clinical specimens. Anal Biochem 1993; 213:414-421.
16. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150:76-85.
17. Busse D, Cosme J, Beaune P, Kroemer HK, Eichelbaum M. Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethytation of verapamit in humans. Naunyn-Schmiedeberg's Arch Pharmacol 1995; 353:116-121.
18. von Richter O. Expression and Function of Drug Metabolizing Enzymes and the ABC-Transporter P-Glycoprotein in Human Small Intestine and Liver [Dissertation]. University of Tübingen, Germany: Faculty of Chemistry and Pharmacy; 2000.
19. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, et al. The rote of the CYP2C9-Leu359 attetic variant in the totbutamide polymorphism. Pharmacogenetics 1996; 6:341-349.
20. Griese EU, Läpple F, Eichelbaum M. Detection of CYP2C19 alleles *1, *2 and *3 by multiplex polymerase chain reaction. Pharmacogenetics 1999; 9:389-391.
21. Drocourt L, Pascussi JM, Assenat E, Fabre JM, Maurel P, Vilarem MJ. Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes. Drug Metab Dispos 2001; 29:1325-1331.
22. Henderson L, Yue QY, Bergquist C, Gerden B, Artett P. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54:349-356.
23. Chen XP, Tan ZR, Huang SL, Huang Z, Ou-Yang DS, Zhou HH. Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. Clin Pharmacol Ther 2003; 73:264-271.
24. Lown KS, Kotars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994; 22:947-955.
25. George J, Liddle C, Murray M, Byth K, Farrell GC. Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. Biochem Pharmacol 1995; 49:873-881.
26. Powell H, Kitteringham NR, Pirmohamed M, Smith DA, Park KB. Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype. Pharmacogenetics 1998; 8:411-421.
27. Shimamoto J, Ieiri I, Urae A, Kimura M, Irie S, Kubota T, et al. Lack of differences in diclofenac (a substrate for CYP2Cg) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele. Eur J Clin Pharmacol 2000; 56:65-68.
28. Yasar U, Eliasson E, Forstund-Bergengren C, Tybring G, Gadd M, Sjoqvist F, et al. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol 2001; 57:729-735.
29. Brenner SS, Herrlinger C, Dilger K, Murdter TE, Hofmann U, Marx C, et al. Influence of age and cytochrome P450 2C9 genotype on the steady. state disposition of diclofenac and celecoxib. Clin Pharmacokinet 2003; 42:283-292.
30. Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ, et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anti-coagulation therapy. Pharmacogenetics 1995; 5:389-392.
31. Aithat GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353:717-719.
32. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287:1690-1698.
33. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K. CYP2C9 IIe359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 2000; 10:95-104.
34. Lee CRr Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12:251-263.